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Synopsis (241 words) 16 
Antibiotic (antibacterial) resistance is a serious global problem and the need for new 17 
treatments is urgent. The current antibiotic discovery model is not developing new agents at 18 
a rate that is sufficient to combat present levels of antibiotic resistance. This has led to fears 19 
of the arrival of a ‘post antibiotic era’.  Scientific difficulties, an unfavourable regulatory 20 
climate, multiple company mergers and the low financial returns associated with antibiotic 21 
drug development led to the withdrawal of many pharmaceutical companies from the field. 22 
The regulatory climate has now begun to improve, but major scientific hurdles still impede 23 
the discovery and development of novel antibacterial agents. To facilitate discovery activities 24 
there must be increased understanding of the scientific problems experienced by 25 
pharmaceutical companies. This must be coupled with addressing the current antibiotic 26 
resistance crisis so that compounds and ultimately drugs are delivered to treat the most 27 
urgent clinical challenges. By understanding the causes of the failures and successes of the 28 
pharmaceutical industry’s research history, duplication of discovery programmes will be 29 
reduced so increasing the productivity of the antibiotic drug discovery pipeline by academia 30 
and small companies. The most important scientific issues to address are getting molecules 31 
into the Gram-negative bacterial cell and avoiding their efflux. Hence screening programmes 32 
should focus their efforts on whole bacterial cells rather than cell-free systems. Despite 33 
falling out of favour with pharmaceutical companies, natural product research still holds 34 
promise for providing new molecules as a basis for discovery.  35 
Introduction 36 
Antibiotic resistance is a serious global problem and the need for new treatments is urgent. 37 
Antibacterial drugs have revolutionised our ability to control bacterial disease, and their 38 
clinical availability has led to dramatic decreases in morbidity and mortality.1 As such, these 39 
therapeutics underpin modern medicine. Despite the integral role of antibiotics in the 40 
maintenance of our modern lifestyle, they are undervalued in both cost and significance by 41 
society. Over the past century, their use has provided a strong selective pressure on micro-42 
organisms, leading to preferential survival and spread of those harbouring antibiotic 43 
resistance mechanisms. Multi-drug resistance (MDR) is now commonplace amongst 44 
bacterial pathogens and antibiotic resistance now affects all antibiotic classes.2 This is 45 
particularly worrisome in the case of Gram-negative bacteria, (e.g. Pseudomonas 46 
aeruginosa and Acinetobacter baumannii) for which treatment options are already limited.3 47 
The “broken” economics of antibacterial research and development (R&D) is often quoted as 48 
the main reason for a lack of new therapies but the truth is it is hard to discover new 49 
antibacterial drugs, and the science is not sufficiently advanced to enable efficient and 50 
effective antibacterial drug discovery.  This has led to fears of a ‘post antibiotic era’. It has 51 
been proposed that between 5 and 20 novel antibacterial drugs need to enter the clinical 52 
development pipeline in order to effectively contend with the current resistance problem. 53 
However, given the attrition rate within the existing drug discovery model, a minimum of 200 54 
discovery programmes would optimistically be needed in order to achieve this outcome. 55 
Hence, new approaches to antibiotic discovery are needed.  56 
The antibiotic pipeline is not what it once was.4 Pharmaceutical companies that were once 57 
the main provider of novel antibiotic molecules withdrew from the late 1990s to the present 58 
day because of their lack of success and low financial returns in delivering new antibacterial 59 
drugs to the market.5 The environment of discovering and developing new antibiotics was 60 
different during the so called ‘golden era’ of drug discovery. Antibiotics worked remarkably 61 
well because resistance was low and physicians had access to a variety of efficacious 62 
antibiotics. The objectives of antibiotic R&D programmes tended to be around improved 63 
pharmacology to achieve less frequent dosing e.g. once a day, rather than innovative new 64 
antibiotics. Natural product screening strategies tended to result in rediscovery of rather than 65 
new compounds. There was also no need to take on the speculative improvement of natural 66 
products with undesirable properties, such as toxicity.  Today, only a few large companies, 67 
including GlaxoSmithKline, Novartis, Merck and Roche actively research and develop 68 
antibiotics, with many of the historically major antibiotic providers (Bristol-Myers Squibb, 69 
Bayer and Eli Lilly), having left the area.  70 
Industry has discovered few new antibiotics, and increasingly this activity is performed by 71 
academia and the private sector in the form of small companies (small medium enterprises; 72 
SMEs) (Table 1).6,7 Furthermore, programmes that have advanced to late stage clinical 73 
evaluation or have had marketing approval have emerged from projects that had originated 74 
in large companies and subsequently licensed to SMEs (e.g. ceftazidine-avibactam).  75 
Successful strategies include semi-synthetic natural products such as dalbavancin, novel 76 
natural product based chemistry e.g. omadacycline, eravacycline, and plazomycin, novel 77 
lactamase inhibitor chemistry, e.g. vaborbactam and fast-following approaches e.g. tedizolid 78 
and cadazolid. What is clear is that innovative chemistry is a key contributor to success.  79 
During the last two decades, antibacterial R&D has suffered from changing clinical and 80 
investor priorities as the focus moved from MRSA to C. difficile and most recently to Gram-81 
negative bacteria.  The changing regulatory advice also created uncertainty and additional 82 
financial risks. The recent regulatory focus for antibiotics and a collective will to create 83 
innovative regulatory pathways for antibacterial drugs should create an environment that will 84 
stimulate discovery, research and development. The community now needs to address other 85 
barriers to success. 86 
SMEs and academia will continue to lead future antibiotic drug discovery efforts6 but they 87 
can only advance new therapies so far. The clinical development capabilities of 88 
pharmaceutical companies and their supply chain are essential components in delivering 89 
new therapies and patient benefits. The future delivery of new therapies will require effective 90 
partnerships between all stakeholders. By learning from its past failures and successes, 91 
pharmaceutical companies should work with academia, charities and SMEs to provide a 92 
more effective antibiotic discovery model.  93 
It has become clear that antibacterial innovation is needed now and in the long-term. 94 
Discovering new antibiotics that are immune to resistance development is unlikely. Training 95 
and infrastructure must be put in place to create the capabilities and capacities required to 96 
deliver new antibacterial therapies regularly over decades and centuries. This generation 97 
may be the last to benefit from cheap antibiotics. This is a critical time and stakeholders’ 98 
actions now will be judged by historians. We should endeavour to create a solid foundation 99 
for future generations to continually respond and innovate as they face their antimicrobial 100 
resistance (AMR) challenges. 101 
 102 
Which antibacterials are needed? 103 
As antibacterial discovery shifts towards an academia/SME-driven discovery activity there is 104 
a risk that research funding (called ‘push’) rather than the clinical need (called ‘pull’) will 105 
define the active programmes. Research-led programmes without consideration of clinical 106 
use, manufacturing, regulatory practices, feasibility of clinical study designs and 107 
reimbursement, are inefficient and probably futile activities. Recently, the WHO published a 108 
list of bacteria for which new antibiotics are urgently needed.8 The next step is to provide 109 
internationally agreed target product profiles (TPPs) that will define what the properties of 110 
suitable antibacterial therapies are. Pharmaceutical companies have detailed descriptions of 111 
what they consider ideal and acceptable characteristics for new antibacterials. These include 112 
indication, patient identification, potency, efficacy, pharmacology, toxicology, safety and 113 
dosage etc. These TPPs could be used by other researchers to ensure that their research is 114 
aligned with the most urgent medical needs. TPPs could also be used by funders and 115 
investors to select projects most likely to have clinical impact. If this is not done, there will 116 
continue to be research on new antibiotics and their development that does not address the 117 
most urgent needs.  118 
 119 
Targets for monotherapy  120 
The emergence and spread of antibiotic resistant bacteria is responsible for the dwindling 121 
number of effective antibacterials. If the success of a new drug is to be ensured, the 122 
potential to develop resistance and the consequences of resistance must be determined. 123 
Basic studies are needed to estimate the potential for developing resistance such as 124 
determining the MIC, resistance frequencies, concentrations for preventing mutation 125 
selection and exploring the consequences of resistance mechanisms. These should be 126 
researched in the early stages of drug discovery.9 In the past, many had hoped that lack of 127 
the emergence of resistance in animal models of infection might indicate that resistance may 128 
not be an issue in the clinic, but this does not always prove to be the case (e.g. 129 
GSK2251052/AN3365).10  130 
Target validation plays a central role in the development of a successful therapeutic. The 131 
traditional view of antibacterial target validation was that an essential protein or process is a 132 
good target. Target essentiality is now viewed as the beginning of the validation process, as 133 
opposed to the end. To develop novel drugs, there needs to be a focused effort to 134 
understand the biology of the target and impact of target inhibition. This will provide insights 135 
into how resistance could occur or how essentiality could be bypassed when that target is 136 
inhibited. For instance, before screening candidate inhibitors against a potential target, 137 
genetic studies to assess the mutability of a drug-binding pocket should be undertaken. 138 
Such studies would reveal how likely mutations that alter the drug target and confer 139 
resistance will occur. Studies should also be carried out to determine whether changes to 140 
the drug target affect the fitness of the bacterium and its ability to cause infection.  141 
Considerable advances have been made over the last decade in identifying gene products 142 
that are important or essential to bacterial physiology and pathogenic attributes. As a result, 143 
there have been numerous suggestions in the literature that such factors could comprise 144 
novel targets for new antibiotics. However, there is a considerable gap between identifying 145 
an essential or important bacterial factor, and inhibitors that are able to form the basis for 146 
developing a new drug. This is because a drug discovery programme needs to identify 147 
inhibitors that are amenable to medicinal chemistry which can provide the basis of a new 148 
drug.  149 
Academia can contribute towards the basic understanding of bacterial cellular processes, 150 
pathogen biology and pathways that may influence resistance development. A better 151 
understanding in this area could help to avoid some of the problems encountered in the past 152 
regarding target validation and resistance.  It is probable that both small compounds and 153 
natural products that provide a good basis for antibacterial drug monotherapies have been 154 
identified. Any new targets will require extensive validation before being developed further. 155 
Good monotherapies comprise a single compound that targets multiple essential protein 156 
activities and for which multiple mutations to the gene encoding the target, or the evolution of 157 
target modifying enzymes, antibiotic degrading enzymes, efflux pumps, or all of these are 158 
needed to develop clinically relevant resistance. Inhibiting the products of single genes, 159 
whether they are essential or conditionally essential e.g. virulence or pathogenicity factors, is 160 
unlikely to lead to effective treatment by a drug containing only one small compound or 161 
natural product.    162 
 163 
Screening: Overcoming the Gram-negative permeability barrier  164 
The discovery of novel, broad and narrow spectrum inhibitors of Gram-negative bacteria has 165 
proven difficult. The last broad-spectrum class of antibacterial agents to enter the clinic was 166 
the quinolones, discovered in the 1960s.11 This is due to their intrinsic resistance to many 167 
different drugs. This is largely attributed to the architecture of the Gram-negative cell 168 
envelope and multi-drug efflux pumps. The outer membrane and the efflux machinery work 169 
together to reduce the intracellular concentration of many different types of antibiotic so that 170 
the bacterium resists the action of a range of structurally diverse, antibacterial compounds.12 171 
The differences in antibiotic activity between Gram-positive and Gram-negative bacteria is 172 
rarely (e.g. daptomycin)13 due to target differences between the two groups of organisms, 173 
but instead is a result of the additional permeability and efflux barrier which Gram-negative 174 
bacteria possess.9,14  175 
There remains a fundamental lack of understanding regarding the physiology and 176 
permeability properties of the Gram-negative cell envelope. Academia play a pivotal role 177 
increasing knowledge in this area, driving new basic research on how to avoid efflux and 178 
ensure the entry of drugs to the bacterial cytoplasm. The generation of ‘rules of entry’, 179 
regarding the chemical properties that are required of compounds to accumulate within the 180 
cytoplasm of Gram-negative bacteria and reach their respective intracellular targets will 181 
greatly aid the development of novel broad-spectrum antibiotics. The recent findings of 182 
Richter et al15, will help generate these rules. There has been some progress improving 183 
activity of the oxazolidinone class of drugs against Escherichia coli and identifying the 184 
structural properties required to penetrate cells.16 Furthermore, a complete understanding of 185 
the orientation and binding of lipopolysaccharide molecules (LPS) on the outer monolayer of 186 
the Gram-negative outer membrane could facilitate the development of cationic molecules to 187 
disrupt it. To successfully develop a new antibiotic to treat infections by Gram-negative 188 
bacteria, the ability of the drug and whether it is susceptible to efflux mechanisms must be 189 
tracked throughout the drug optimisation process. This can be achieved by including whole-190 
cell screening assays comparing activities in wild type and in efflux mutants. However, care 191 
over the choice of efflux mutants is essential; point mutations inactivating the transporter 192 
process whilst maintaining the presence of the protein should be used rather than deletion 193 
mutants.17 Recent clinical isolates should be included during optimization programmes to 194 
ensure compounds are effective against those bacteria giving current clinical problems.  195 
The importance of overcoming the barriers to antibiotic entry in Gram-negative pathogens 196 
has also been highlighted in the, ‘Scientific Roadmap for Antibiotic Discovery’, from the Pew 197 
Charitable Trust.18 The primary objectives outlined for antibiotic drug development include 198 
overcoming the permeability barrier of particularly impermeable, Gram-negative bacteria and 199 
subsequently tailoring chemical matter for this discovery process.  200 
 201 
Sources of antibacterial compounds 202 
Natural products dominate the existing antibacterial compendium, with around 75% of 203 
available antibiotics being of natural origin.19 The importance of the natural world as a source 204 
of antibacterial drugs is also evident from the history of the antibiotic pipeline, which has 205 
continued to be re-stocked with semi-synthetic derivatives of established, natural product 206 
classes. However, despite previous successes, the labour intensive, low-throughput nature 207 
of natural product drug discovery and diminishing returns eventually caused the 208 
pharmaceutical industry to stop active research in this area. During the late 1990s, the focus 209 
of attention shifted to synthetic compound libraries, which were utilised in high-throughput 210 
screens to search for novel, target specific inhibitors in vitro.9 This method of drug discovery 211 
did not prove fruitful as it did not discover novel antibacterial compounds amenable to drug 212 
discovery.5 The failures of the genomic era to deliver novel drug targets and scaffolds, 213 
coupled with the threat of a ‘post-antibiotic era’ have prompted a revival of natural product 214 
drug discovery in both academia and the biotechnology sector. As pharmaceutical 215 
companies are less active in this area, they cannot offer a sustainable contribution to natural 216 
product discovery on their own. It is likely that many readily accessible sources of potent, 217 
broad-spectrum antibacterial compounds have already been exhausted by past discovery 218 
efforts by pharmaceutical companies.  Therefore, natural product sources should be 219 
investigated as a source for potential, untapped leads, especially when combined with novel 220 
assays.  221 
Slow-growing, uncultivable environmental organisms may represent a large potential 222 
untapped resource of novel antibiotics, and recent innovations could allow natural product 223 
discovery to be carried out in a sustainable manner. For instance, the development of the in 224 
situ culture device, the iChip, has allowed the high throughput cultivation of environmental 225 
microorganisms.20 The merit of this device can be seen from the discovery of teixobactin, a 226 
compound of a novel antibiotic class which possesses activity against Gram-positive 227 
bacteria but hits a well characterized target – the bacterial cell wall biosynthesis machinery.21 228 
Alternatively, cryptic biosynthetic pathways could be activated (which lead to the production 229 
of novel secondary metabolites with antibiotic activity).22 Metagenomics ( analysis of 230 
genomes from DNA from microorganisms in environmental samples) could be used to 231 
investigate the secondary metabolite diversity of non-cultivatable environmental organisms. 232 
Lastly, a key process in natural product drug discovery is the inclusion of de-replication 233 
techniques such as high-resolution LC-MS/MS, which ensures the elimination of previously 234 
characterised compounds from further study. 235 
It is possible that all the antibacterial molecules amenable to drug discovery have been 236 
identified and that the search for novelty may not pay off. In this case, substantial investment 237 
into innovative chemistry on and around the known molecules would be prudent to 238 
determine the advances that can be made. This less speculative, directed chemistry is 239 
surprisingly difficult to fund and yet is a successful strategy to overcome resistance and or 240 
side effects. 241 
It may be that all the good targets for single drug therapy have been identified. Therefore, to 242 
find alternative chemical classes to inhibit these targets investment in innovative chemistry is 243 
required.  244 
 245 
Efficacy 246 
Animal models of bacterial infection can be highly predictive of efficacy in clinical use. 247 
Marketed antibiotics perform well in these models and researchers have come to expect 248 
high levels of bacterial kill by candidate drugs. However, some compounds with modest 249 
potency in in vivo studies may have been overlooked or de-prioritized in optimization 250 
programmes. The community does not know what level of animal model efficacy is the 251 
minimum necessary to deliver clinical benefit for a monotherapy. Until recently a three-log 252 
reduction in bacterial burden was considered the necessary level of efficacy to continue 253 
research and development in a pharmaceutical company. Many now consider a two-log 254 
reduction adequate and indicative of potential clinical utility.23 Is a one-log reduction or just 255 
bacteriostasis sufficient? Research on this area is urgently required. 256 
 257 
Resistance 258 
The community urgently requires evidence-based guidelines from regulators on what levels 259 
of in vitro evolution to give drug resistance are acceptable for antibiotics in development. 260 
Current target product profiles for monotherapy products vary by orders of magnitude from 261 
<10-8 to <10-12. The metric may depend on the consequences of resistance, what increase in 262 
MIC of a drug resistant mutant provides, and whether the mutant is attenuated in infection 263 
models. Understanding all aspects of resistance and transmission of drug-resistant bacteria 264 
is essential if new drugs are to have longevity.24  265 
 266 
A key metric of an antibiotic in considering it as a new monotherapy is the mutant prevention 267 
concentration (MPC). This is the drug concentration at which no mutants survive. When a 268 
culture of drug-susceptible susceptible bacteria is exposed to a new antibacterial compound, 269 
pre-existing rare point mutations that confer resistance to the compound may be selected.25 270 
The activity of the compound against these insusceptible mutants is likely to be less than for 271 
wildtype bacteria and a multiple of the MIC of the compound may be required to kill or inhibit 272 
a mutant’s growth. To suppress resistance development in clinical use, bacteria must be 273 
exposed to a concentration of the antibiotic which kills both the susceptible and first step 274 
mutants of the species. Typically, bacteria require two or more mutations to become 275 
insusceptible at the MPC and this happens rarely in vitro, but is not uncommon once a drug 276 
has been licensed.  One example of this is with the fluoroquinolone drugs (note, mutations 277 
have been found in the same and different genes).26 278 
If the MIC of a strain with a first-step mutation does not greatly increase, only a modest 279 
increase in drug concentration is required to achieve the MPC. If there is a big increase in 280 
the MIC of the first step mutation a much higher dose is required to achieve the MPC. To 281 
stop resistance developing in clinical use, bacteria at the site of infection must be exposed to 282 
free-drug concentrations above the MPC for a significant period of the dosing interval (e.g. 8 283 
hours). In practice, this means that antibacterials have to be potent and well tolerated to 284 
achieve these exposures. Too few antibacterial drug R&D programmes demonstrate 285 
understanding of the pharmacology of managing resistance and fail to build this into their 286 
programmes. When thoroughly analysed, many of the novel target – new compound 287 
programmes fail to adequately address resistance because sufficient exposure to doses 288 
above the MPC cannot be achieved.  289 
 290 
Combinations 291 
As monotherapies have proven so challenging to discover and develop, much focus has 292 
turned towards antibacterial combinations and it here that academia has much to offer. This 293 
approach is much like those adopted for the treatment of HIV or tuberculosis, where different 294 
drugs with different modes of action are used as part of a combination treatment. When 295 
used, current combinations of antibiotics, such as those used to treat patients with sepsis, 296 
focus is on covering Gram-positive and Gram-negative bacteria as well as ensuring 297 
adequate drug concentration at the probable site of infection.27  298 
There is much literature on ad hoc combinations of antibiotics and their effects on laboratory 299 
strains and clinical isolates; this has led to suggestions of novel combinations that could be 300 
used to treat Gram-negative bacterial infections.  However, definitive large-scale studies 301 
have been lacking. This area would be enabled by widespread open access to well 302 
characterized drug-resistant and multi-drug resistant isolates. Double, triple and quadruple 303 
combinations that are able to inhibit challenging strains may be feasible and might be 304 
unpredictable. As resources are the only barrier, exhausting combination opportunities now 305 
from drugs already available for human use should be investigated.  Unfortunately, such 306 
studies are rare; the focus on resolving the crisis of AMR has focused on establishing 307 
economic incentives to stimulate pharmaceutical companies to stay (or return) to this field. 308 
Furthermore, companies have no incentive to support studies on combinations of old drugs 309 
and has been generally unsupportive of this approach. 310 
There are examples in the literature of antibiotics and non-antibacterial marketed drugs that 311 
could be used to potentiate the activity of an antibiotic against insusceptible or drug-resistant 312 
bacteria sometimes called ‘resistance breakers’.28 The marketed drug may alter permeability 313 
through the bacterial cell membrane, interfere with efflux or act via alternative mechanisms. 314 
While the titles of some publications look appealing it is unclear whether any clinically useful 315 
new combinations have emerged. Not only does the activity of combinations of drugs for 316 
multi-drug resistant clinical isolates need to be established, but the primary pharmacology of 317 
the drug to be combined with an antibiotic may not be amenable to clinical use in a co-318 
delivered combination. For example, the dose may be much higher than approved dose. 319 
Alternatively, the toxicity and safety at higher doses, plus the requirement for matched or 320 
manageable pharmacology of the combination must be considered.  321 
Instead of using marketed drugs, some are developing bespoke non-antibiotic and antibiotic 322 
combinations that disrupt the bacterial cell membrane and increase antibiotic access (e.g. 323 
Spero Therapeutics). Industry, SMEs and academics working on novel targets and 324 
chemistries have created programmes that have failed as monotherapies; these may provide 325 
options for the creation of novel combination products. While the development may be 326 
challenging and risky, partnering the right projects could create useful new therapies. LpxC 327 
is an essential enzyme required for LPS biosynthesis in Gram-negative bacteria.29 As 328 
inhibition of LpxC tends to increase susceptibility to other antibacterials, combination of 329 
LpxC-inhibitors with antibiotics may be a fruitful line of discovery.  330 
 331 
Anti-virulence compounds 332 
During the genomic-led antibacterial discovery period the community thought it was limited 333 
by the number of targets for antibiotics. As a result, inhibition of conditionally essential 334 
single-gene virulence targets was proposed as a way to increase the number of targets 335 
available. While there are claims that inhibition of virulence targets will circumvent resistance 336 
development, drugs targeting virulence will be subject to evolutionary pressures and it is 337 
probable that resistance will develop, particularly where small compounds are used.  Anti-338 
virulence monoclonal antibodies, may be less susceptible to the evolution of resistance.  339 
This is because of the much larger surface area through which they interact.   340 
 341 
Funding  342 
Despite spending considerable resources over the last two decades, the pharmaceutical 343 
industry has largely failed to discover or deliver new antibacterial drugs. Future discovery 344 
programmes will have to work smarter, use effective collaboration and be adequately 345 
resourced for a sustained period to have any chance of delivering new antibacterials. Such 346 
collaborations have started to emerge such as the Community for Open Antimicrobial Drug 347 
Discovery,30 where they have a screening facility and will take compounds and screen them.  348 
What is lacking is a seamless flow from academic discovery to SME and large 349 
pharmaceutical companies so that the requisite early discovery hit to lead optimization 350 
research can be carried out.  Historically, the area of antibiotic drug discovery was 351 
considered the domain of large pharmaceutical companies and consequently, the existing 352 
funding structure for academia and SME remains inadequate for the task. This is despite the 353 
advent of CARB-X,31 The Global Antibiotic Research and Development Partnership 354 
(GARDP),32 and initiatives by numerous national funding agencies. Addressing AMR 355 
requires a sustained and concerted effort with all stakeholders working together to make the 356 
case for unprecedented levels of funding and delivering new processes to use that funding 357 
effectively. 358 
 359 
How do we prioritize? 360 
The last two decades have shown that chasing novelty in terms of targets or compound 361 
scaffolds has been inefficient and that time establishing firm foundations of science upon 362 
which to build future activities is required.  We recommend that (1) investment is needed to 363 
provide innovative chemistry on and around known clinically effective drug scaffolds; (2) 364 
alternative ways to inhibit the function of clinically validated targets; (3) understand 365 
resistance mechanisms and how they can be inhibited; (4) understand the utility of animal 366 
models and the risks around reducing drug-efficacy hurdles; and (5) establish the levels of in 367 
vitro resistance development that are unacceptable. 368 
Currently, too many academic and SME programmes are research-push driven without 369 
appreciation of the manufacturing, regulatory and clinical hurdles their approaches present. 370 
A substantial and sustained programme of investment in training of the next generation of 371 
AMR researchers to equip them to understand how to create feasible projects is required. To 372 
our knowledge there are at least three new doctoral training programmes designed to fill this 373 
gap.33-35 More are needed across the world. 374 
Society must not assume short term solutions can be found and there is no point in 375 
prioritizing programmes that are unlikely to be feasible in the next 10 to 30 years. Investment 376 
must be prioritized on the feasible projects and where possible additional funding used for 377 
more speculative programmes. 378 
 379 
Conclusions and future perspectives  380 
There is still much to discover in regards to bacterial physiology that would benefit the field 381 
of antibiotic R & D and so academia has an essential role to play. Academic research groups 382 
can assist by undertaking a systems biology approach to the understanding of potential 383 
targets, and increasing our understanding of the permeability barrier and multi-drug efflux in 384 
Gram-negative bacteria. A new paradigm for preclinical research has been proposed.36 It 385 
should be helpful to those engaged in early drug discovery. However, early discovery 386 
research should be in partnership with SMEs and large companies and not in isolation in 387 
academia.  Otherwise, there is the danger of spending considerable time and funding on 388 
research that will never deliver a new drug. 389 
The natural world remains the largest source of novel chemical drug scaffolds and natural 390 
product drug discovery remains a viable option in the search for new antibiotic compounds. 391 
Advances in bacterial culture techniques, molecular biology and metagenomics will continue 392 
to improve the ease and cost effectiveness of natural product drug discovery, which have 393 
been a major limiting factor in the past. Screening procedures must include whole-bacterial 394 
cell assays, addressing the issue of bacterial permeability and efflux early in the discovery 395 
process.37 Additionally, the generation of training schemes by and with pharmaceutical 396 
companies, in relation to all aspects of the pipeline and including natural product drug 397 
discovery, are essential and will ensure that expertise is passed to future researchers.  398 
Investment should also be made into the study of previously characterized lead compounds 399 
that did not reach the clinic, so called ‘old leads’. The reasons that led these compounds to 400 
be dropped from further development vary, ranging from financial issues, dosing problems, 401 
to trial design and toxicity issues. It may be that there is now sufficiently improved 402 
technology and expertise to develop these as efficacious, safe antibacterials, and the study 403 
of ‘old leads’ could provide an additional source of novel antimicrobials. A freely accessible 404 
database of antibiotics that were not developed has been recently launched, Antibiotic DB;38 405 
prevent replication of discovery efforts. Another database comprising ‘old natural product 406 
leads’ would also help the community. However, care must be taken to review all previous 407 
research on the compound(s) of interest to ensure that the failures of the past are not 408 
repeated. 409 
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 Table. Source of discoveries, clinical developer and recently approved antibiotics (in alphabetical order and by development phase) 
Antibiotic Discovered by Developed by and transfer between companies over time Status 
Approved since 2015    
Ceftazidime+avibactam 
(Avycaz) 
Sanofi  Novexel; AstraZeneca-Forest/Actavis Approved in USA and EU 
Ceftobiprole (Zevtera) Roche Basilea Not approved in USA. Approved 
in13 EU countries plus several 
others 
Ceftolozane+tazobactam 
(Zerbaxa) 
Astellas Calixa, Cubist=Merck Approved in USA and EU 
Dalbavancin (Xydalba) Lepetit Research 
Center/Vicuron 
Pfizer, Durata, Actavis Approved in USA and EU 
Oritavancin (Orbactive) Eli Lilly Intermune, Targanta, The Medicine Company Approved in USA and EU 
Solithromycin, (Cemprex) Optimer Cempra Approved in USA and EU 
Tedizolid (Sivextro) Dong-A Trius, Bayer/Cubist=Merck Approved in USA and EU 
New Drug Application (NDA) submitted 
Carbavance 
(vaborbactam+meropenem) 
Rempex Rempex, The Medicines Company Phase 3 
Delafloxacin Wakunaga  Abbott, Wakunaga, Rib-X (Melinta Therapeutics) Phase 3 
In development    
BC-(Lefamulin) 3781  Sandoz/Novartis Nabriva, Forest/Actavis, Nabriva Phase 3 
Cadazolid Actelelion Actelion Pharmaceuticals Phase 3 
Iclaprim Hoffman LaRoche, 
Arpida 
MotifBio PLC Phase 3 
Imipenem/cilastatin + 
Relebactam (MK- 7655) 
Merck & Co Inc Merck & Co Inc Phase 3 
Omadacycline 
  
Paratek  Paratek/Bayer, Paratek/Merck, Paratek Novartis, Paratek Phase 3 
Plazomicin Isis Achaogen Phase 3 
S-649266 Shionogi Shionogi Inc Phase 3 
Solithera (Solithromycin) Cempra Inc,   
Taksta (fusidic acid) Leo Pharmaceuticals Cempra Phase 3 
Eravacycline TP- 434  Harvard University Tetraphase Phase 3 
Zabofloxacin Dong Wha Dong Wha Pharmaceuticals Co Ltd Phase 3  
Aztreonam + avibactam  Actavis, Allergon PLC, Astra-Zeneca, Pfizer Phase 2 
CG400549 Crystal Genomics Inc Crystal Genomics Inc Phase 2 
Afabicin (Debio 1450) Debiopharm 
International SA 
  
ETX0914 Astra-Zeneca Entasis Therapeutics Inc Phase 2 
Finafloxacin Centre for Natural 
Product Research 
Singapore-Institute of 
Merlion Pharmaceuticals Pte Lted Phase 2 
Molecular and Cell 
Biology 
Gepotidacin (GSK2140944) GSK GSK Phase 2 
MRX-1 MicuRx 
Pharmaceuticals Inc 
 Phase 2 
Nemonoxacin  TaiGen  Procter & Gamble, Warner Chilcott,TaiGen Phase 2 
Brilacidin PMX-30063  University of 
Pennsylvania 
Polymedix, Cellceutix Corporation Phase 2 
POL7080 University of Zurich  Polyphor, Roche, Polyphor Phase 2 
Ramoplanin Merrell Dow Research 
Institute 
Nanoterapeutics Inc Phase 2 
Ridinilazole (SMT19969) Summit 
Therapeutics Inc 
 Phase 2 
WCK 4873 Wockhardt Ltd  Phase 2 
CRS3123 Crestone Inc.  Phase 1 
ETX2514SUL Entasis Therapeutics 
Inc. 
 Phase 1 
GSK*3342830 GlaxoSmithKline PLC 
(Shionogi licensee) 
 Phase 1 
KBP-7072 KBP BioSciences 
Pharmaceutical 
Technical Co. Ltd. 
 Phase 1 
LCB0 1-0371 LegoChem 
Biosciences Inc 
 Phase 1 
MGB-BP-3 MGB Biopharma Ltd  Phase 1 
OP0595 (RG6080) Meiji Seika Pharma 
Co. Ltd./Fedora 
Pharmaceuticals Inc 
(Roche licensee) 
 Phase 1 
SPR741 Spero Therapeutics   
TD-1607 Theravance 
Biopharma Inc. 
 Phase 1 
TP-271 Tetraphase 
Pharmaceutials Inc. 
 Phase 1 
TP-6076 Tetraphase 
Pharmaceuticals Inc. 
 Phase 1 
WK 771 Wockhardt Ltd  Phase 1 
WK 2349 Wockhardt Ltd  Phase 1 
Zidebactam + cefepime 
(WCK 5222) 
Wockhardt Ltd  Phase 1 
Drugs no longer under development 
AFN-1252/Debio 1450 University of 
Toronto 
Affinium, Debiopharm SA  
Radezolid (RX-1741) Yale University Rib-X (Melinta Therapeutics)  
Ceftaroline + avibactam  Actavis Allergon PLC, Astra-Zeneca, Pfizer  
BAL30072 Basilea 
Pharmaceutica Ltd 
  
JNJ-(Avarofloxacin) Q2  J&J (Janssen 
Pharm.) 
Furiex, Forest/Actavis  
 
Bold font indicated those agents discovered by academia and SMEs. 
Adapted from from references.7,39,40 
